Remove 2009 Remove FDA Remove Side effects
article thumbnail

Drug side effects should be easier to understand

World of DTC Marketing

” Drug facts boxes are needed, but the FDA disagrees. According to the AMA one of the key reasons for non-adherence is that patients may be frightened of potential side effects. From seeing those side effects experienced by someone else, it may have led them to believe the medication caused those problems.

article thumbnail

Basilea preps key US filing for MRSA antibiotic ceftobiprole

pharmaphorum

The intravenously-administered cephalosporin drug met its objectives in the ERADICATE study in adults with bacterial bloodstream infections caused by Staphylococcus aureus (SAB), setting up an FDA filing before the end of the year, said the Swiss pharma. The overall success rate was 69.8% with ceftobiprole compared to 68.7%

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Thursday pharma headlines

World of DTC Marketing

As early as 2009, Merck knew of more than 200 reports of depression, including suicidal thoughts, in men taking Propecia, according to an internal “risk management” assessment from that year. Food and Drug Administration (FDA) is meant to help patients and warn of potential drug side effects but a Vice report indicates something more.

Pharma 180
article thumbnail

Can a nasal spray tackle agitation in autism?

Pharmaceutical Technology

Janssen’s Risperdal (risperidone), a second-generation antipsychotic , got its first FDA approval for autism-related irritability for children over the age of five, in 2006. Generic versions of both drugs are now available. Generic versions of both drugs are now available.

article thumbnail

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

Limitations of monoclonal antibody therapies Regulatory approvals from the US Food and Drug Administration (FDA) for aducanumab and lecanemab – and likely very soon for donanemab also – opened a route for different therapeutic modalities and other relevant disease targets, such as tau. Lowe SL, Duggan Evans C, et al. 2009;6(2):144–51.

article thumbnail

Ep. 001 – John Mack Podcast Transcript

Pharma Marketing Network

So, this was back in 2009, and I hosted a Halloween party at my house, and I decided to dress up as Hunter S. Yeah, I even wanted to wear the shirt to this FDA meeting. Plus, I don’t think… I don’t know how the FDA would respond to Hawaiian shirt. Yeah, I mean, that’s pretty interesting.

Media 52